CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BetterLife Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BetterLife Pharma Inc
1275 WEST 6TH AVENUE
Phone: (438) 884-8841p:438 884-8841 VANCOUVER, BC  V6H 1A6  Canada Fax: (604) 551-5178f:604 551-5178
Business Summary
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and is a non-hallucinogenic and non- controlled lysergic acid diethylamide (LSD) derivative in development and that is unregulated and therefore can be self-administered. Its synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and is based on honokiol, the active anxiolytic ingredient of magnolia bark. Its pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. It also owns a drug candidate for the treatment of viral infections.
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
7/31/20241/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer AhmadDoroudian 63 5/5/2020 9/1/2007
Chief Financial Officer MoiraOng 49 12/26/2010 12/26/2010
Chief Operating Officer HooshmandSheshbaradaran 67 5/1/2023 8/31/2020
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
IndUS Pharmaceuticals Inc. 25 Olympia Avenue Woburn MA United States

Business Names
Business Name
BETR
ERS Holdings, LLC
IndUS Pharmaceuticals Inc.
8 additional Business Names available in full report.

General Information
Number of Employees: 4 (As of 1/31/2024)
Outstanding Shares: 129,463,096 (As of 9/25/2024)
Shareholders: 46
Stock Exchange: CNQ
Fax Number: (604) 551-5178
Email Address: ir@neurokine.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024